

Serena Spudich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/493975/publications.pdf>

Version: 2024-02-01

113
papers

8,469
citations

57758

44
h-index

48315

88
g-index

115
all docs

115
docs citations

115
times ranked

9731
citing authors

#	ARTICLE	IF	CITATIONS
1	Investigating vascular diseases in people living with HIV by nuclear imaging. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 1576-1582.	2.1	1
2	Cerebrospinal Fluid Viral Load Across the Spectrum of Untreated Human Immunodeficiency Virus Type 1 (HIV-1) Infection: A Cross-Sectional Multicenter Study. <i>Clinical Infectious Diseases</i> , 2022, 75, 493-502.	5.8	15
3	Nervous system consequences of COVID-19. <i>Science</i> , 2022, 375, 267-269.	12.6	242
4	Single-cell multiomics reveals persistence of HIV-1 in expanded cytotoxic T ^H cell clones. <i>Immunity</i> , 2022, 55, 1013-1031.e7.	14.3	61
5	HIV Compartmentalization in the CNS and Its Impact in Treatment Outcomes and Cure Strategies. <i>Current HIV/AIDS Reports</i> , 2022, 19, 207-216.	3.1	6
6	HIV viral transcription and immune perturbations in the CNS of people with HIV despite ART. <i>JCI Insight</i> , 2022, 7, .	5.0	17
7	Central Nervous System Safety During Brief Analytic Treatment Interruption of Antiretroviral Therapy Within 4 Human Immunodeficiency Virus Remission Trials: An Observational Study in Acutely Treated People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e1885-e1892.	5.8	8
8	Assessment of Brain Injury Using Portable, Low-Field Magnetic Resonance Imaging at the Bedside of Critically Ill Patients. <i>JAMA Neurology</i> , 2021, 78, 41.	9.0	124
9	Cognitive trajectories after treatment in acute HIV infection. <i>Aids</i> , 2021, 35, 883-888.	2.2	13
10	Neuropathogenesis of acute coronavirus disease 2019. <i>Current Opinion in Neurology</i> , 2021, 34, 417-422.	3.6	14
11	Preliminary In Vivo Evidence of Reduced Synaptic Density in Human Immunodeficiency Virus (HIV) Despite Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2021, 73, 1404-1411.	5.8	25
12	Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms. <i>Cell Reports Medicine</i> , 2021, 2, 100288.	6.5	121
13	Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppression. <i>PLoS ONE</i> , 2021, 16, e0250987.	2.5	30
14	VZV myelitis with secondary HIV CSF escape. <i>BMJ Case Reports</i> , 2021, 14, e241738.	0.5	1
15	Ischemic Stroke, Inflammation, and Endotheliopathy in COVID-19 Patients. <i>Stroke</i> , 2021, 52, e233-e238.	2.0	31
16	Abrupt and altered cell-type specific DNA methylation profiles in blood during acute HIV infection persists despite prompt initiation of ART. <i>PLoS Pathogens</i> , 2021, 17, e1009785.	4.7	12
17	Coronavirus disease 2019 and neurodegenerative disease: what will the future bring?. <i>Current Opinion in Psychiatry</i> , 2021, 34, 177-185.	6.3	26
18	Prior Stroke and Age Predict Acute Ischemic Stroke Among Hospitalized COVID-19 Patients: A Derivation and Validation Study. <i>Frontiers in Neurology</i> , 2021, 12, 741044.	2.4	4

#	ARTICLE	IF	CITATIONS
19	Minimal detection of cerebrospinal fluid escape after initiation of antiretroviral therapy in acute HIV-1 infection. <i>Aids</i> , 2021, 35, 777-782.	2.2	8
20	Cerebrospinal fluid CD4+ T cell infection in humans and macaques during acute HIV-1 and SHIV infection. <i>PLoS Pathogens</i> , 2021, 17, e1010105.	4.7	9
21	Regional brain volumetric changes despite 2 years of treatment initiated during acute HIV infection. <i>Aids</i> , 2020, 34, 415-426.	2.2	21
22	A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection. <i>Journal of Virus Eradication</i> , 2020, 6, 100004.	0.5	23
23	Stroke Code Presentations, Interventions, and Outcomes Before and During the COVID-19 Pandemic. <i>Stroke</i> , 2020, 51, 2664-2673.	2.0	81
24	Determinants of suboptimal CD4 + T cell recovery after antiretroviral therapy initiation in a prospective cohort of acute HIV-1 infection. <i>Journal of the International AIDS Society</i> , 2020, 23, e25585.	3.0	13
25	Lessons from a neurology consult service for patients with COVID-19. <i>Lancet Neurology</i> , The, 2020, 19, 806-807.	10.2	4
26	Single-cell transcriptional landscapes reveal HIV-1-driven aberrant host gene transcription as a potential therapeutic target. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	75
27	Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019. <i>JAMA Neurology</i> , 2020, 77, 1018.	9.0	748
28	Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19. <i>BMC Neurology</i> , 2020, 20, 248.	1.8	108
29	Cognitive disorders in people living with HIV. <i>Lancet HIV</i> , the, 2020, 7, e504-e513.	4.7	78
30	Liver function test abnormalities in a longitudinal cohort of Thai individuals treated since acute HIV infection. <i>Journal of the International AIDS Society</i> , 2020, 23, e25444.	3.0	7
31	Resting-state neural signatures of depressive symptoms in acute HIV. <i>Journal of NeuroVirology</i> , 2020, 26, 226-240.	2.1	6
32	Switch to dolutegravir is well tolerated in Thais with HIV infection. <i>Journal of the International AIDS Society</i> , 2019, 22, e25324.	3.0	11
33	Treatment of Central Nervous System Manifestations of HIV in the Current Era. <i>Seminars in Neurology</i> , 2019, 39, 391-398.	1.4	8
34	Deep Sequencing Reveals Central Nervous System Compartmentalization in Multiple Transmitted/Founder Virus Acute HIV-1 Infection. <i>Cells</i> , 2019, 8, 902.	4.1	15
35	Very Early Initiation of Antiretroviral Therapy During Acute HIV Infection Is Associated With Normalized Levels of Immune Activation Markers in Cerebrospinal Fluid but Not in Plasma. <i>Journal of Infectious Diseases</i> , 2019, 220, 1885-1891.	4.0	42
36	Predicting Efavirenz Concentrations in the Brain Tissue of HIV-1 Infected Individuals and Exploring their Relationship to Neurocognitive Impairment. <i>Clinical and Translational Science</i> , 2019, 12, 302-311.	3.1	5

#	ARTICLE	IF	CITATIONS
37	Slowly progressive fatal PML-IRIS following antiretroviral initiation at CD4+ nadir of 350 cells/mm ³ despite CD4+ cell count rise to 900 cells/mm ³ . <i>International Journal of STD and AIDS</i> , 2019, 30, 810-813.	1.1	0
38	Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting. <i>Lancet HIV</i> , 2019, 6, e259-e268.	4.7	139
39	Trajectory Analysis of Cognitive Outcomes in Children With Perinatal HIV. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 1038-1044.	2.0	7
40	Neurosyphilis During Acute HIV Infection: A CNS Immunologic and Virologic Characterization. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, e34-e37.	2.1	0
41	HIV persistence in the central nervous system during antiretroviral therapy. <i>Aids</i> , 2019, 33, S103-S106.	2.2	5
42	Exosomal MicroRNAs Associate With Neuropsychological Performance in Individuals With HIV Infection on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 514-522.	2.1	15
43	Defining cerebrospinal fluid HIV RNA escape. <i>Aids</i> , 2019, 33, S107-S111.	2.2	40
44	Potential for early antiretroviral therapy to reduce central nervous system HIV-1 persistence. <i>Aids</i> , 2019, 33, S135-S144.	2.2	13
45	Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells. <i>Clinical Infectious Diseases</i> , 2019, 69, 1345-1352.	5.8	58
46	Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders. <i>Current HIV/AIDS Reports</i> , 2019, 16, 76-81.	3.1	9
47	CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e512.	6.0	50
48	Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance. <i>Journal of Clinical Investigation</i> , 2019, 129, 3339-3346.	8.2	81
49	Acute Retroviral Syndrome Is Associated With High Viral Burden, CD4 Depletion, and Immune Activation in Systemic and Tissue Compartments. <i>Clinical Infectious Diseases</i> , 2018, 66, 1540-1549.	5.8	32
50	Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir?. <i>Journal of Infectious Diseases</i> , 2018, 217, 1024-1032.	4.0	29
51	Longitudinal Trajectories of Brain Volume and Cortical Thickness in Treated and Untreated Primary Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , 2018, 67, 1697-1704.	5.8	67
52	Central Nervous System Inflammation and Infection during Early, Nonaccelerated Simian-Human Immunodeficiency Virus Infection in Rhesus Macaques. <i>Journal of Virology</i> , 2018, 92, .	3.4	33
53	Safety of lumbar puncture procedure in an international research setting during acute HIV infection. <i>Journal of Virus Eradication</i> , 2018, 4, 16-20.	0.5	7
54	Residency Training: Progressive gait difficulty and incontinence in a 40-year-old man with HIV. <i>Neurology</i> , 2018, 91, 1065-1070.	1.1	0

#	ARTICLE	IF	CITATIONS
55	Global Health Neurology: HIV/AIDS. <i>Seminars in Neurology</i> , 2018, 38, 238-246.	1.4	4
56	Distribution of Human Immunodeficiency Virus (HIV) Ribonucleic Acid in Cerebrospinal Fluid and Blood Is Linked to CD4/CD8 Ratio During Acute HIV. <i>Journal of Infectious Diseases</i> , 2018, 218, 937-945.	4.0	15
57	Structural and functional brain imaging in acute HIV. <i>NeuroImage: Clinical</i> , 2018, 20, 327-335.	2.7	34
58	Normalization of Soluble CD163 Levels After Institution of Antiretroviral Therapy During Acute HIV Infection Tracks with Fewer Neurological Abnormalities. <i>Journal of Infectious Diseases</i> , 2018, 218, 1453-1463.	4.0	28
59	Depression and Anxiety are Common in Acute HIV Infection and Associate with Plasma Immune Activation. <i>AIDS and Behavior</i> , 2017, 21, 3238-3246.	2.7	43
60	An explanatory factor analysis of a brief self-report scale to detect neurocognitive impairment among HIV-positive men who have sex with men and transgender women in Peru. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 1297-1301.	1.2	2
61	Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 761-770.	3.1	114
62	High Number of Activated CD8+ T Cells Targeting HIV Antigens Are Present in Cerebrospinal Fluid in Acute HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 108-117.	2.1	31
63	Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2017, 215, 1132-1140.	4.0	50
64	Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection. <i>Aids</i> , 2017, 31, 247-252.	2.2	21
65	Neurological Complications of HIV Infection. <i>Current Infectious Disease Reports</i> , 2017, 19, 50.	3.0	50
66	Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. <i>Journal of Virus Eradication</i> , 2016, 2, 43-48.	0.5	73
67	Past Substance Use Affects Central Nervous System (CNS) Inflammation in Human Immunodeficiency Virus Infection. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	1
68	Cognitive Impairment and Persistent CNS Injury in Treated HIV. <i>Current HIV/AIDS Reports</i> , 2016, 13, 209-217.	3.1	29
69	HIV-Associated Neurologic Disorders and Central Nervous System Opportunistic Infections in HIV. <i>Seminars in Neurology</i> , 2016, 36, 373-381.	1.4	29
70	Neurologic signs and symptoms frequently manifest in acute HIV infection. <i>Neurology</i> , 2016, 87, 148-154.	1.1	59
71	Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. <i>EBioMedicine</i> , 2016, 3, 135-140.	6.1	360
72	Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. <i>Journal of Virus Eradication</i> , 2016, 2, 43-48.	0.5	45

#	ARTICLE	IF	CITATIONS
73	Highlights of the Global HIV-1 CSF Escape Consortium Meeting, 9 June 2016, Bethesda, MD, USA. <i>Journal of Virus Eradication</i> , 2016, 2, 243-250.	0.5	22
74	Neuropsychological Impairment in Acute HIV and the Effect of Immediate Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 393-399.	2.1	42
75	Absence of Cerebrospinal Fluid Signs of Neuronal Injury Before and After Immediate Antiretroviral Therapy in Acute HIV Infection. <i>Journal of Infectious Diseases</i> , 2015, 212, 1759-1767.	4.0	34
76	Neuropathogenesis of HIV: From Initial Neuroinvasion to HIV-Associated Neurocognitive Disorder (HAND). <i>Current HIV/AIDS Reports</i> , 2015, 12, 16-24.	3.1	150
77	Compartmentalized Replication of R5 T Cell-Tropic HIV-1 in the Central Nervous System Early in the Course of Infection. <i>PLoS Pathogens</i> , 2015, 11, e1004720.	4.7	147
78	Cerebral white matter integrity during primary HIV infection. <i>Aids</i> , 2015, 29, 433-442.	2.2	59
79	Phenotypic Correlates of HIV-1 Macrophage Tropism. <i>Journal of Virology</i> , 2015, 89, 11294-11311.	3.4	54
80	CNS reservoirs for HIV: implications for eradication. <i>Journal of Virus Eradication</i> , 2015, 1, 67-71.	0.5	54
81	641Acute Retroviral Syndrome is Associated with Gut Mucosal CD4 Depletion, Inflammation and High Viral and Proviral Burden in Systemic and Tissue Compartments. <i>Open Forum Infectious Diseases</i> , 2014, 1, S32-S32.	0.9	0
82	HIV and other Retroviral Infections of the Nervous System. , 2014, , 885-909.		0
83	HIV Neurology. <i>Seminars in Neurology</i> , 2014, 34, 005-006.	1.4	2
84	Evolving Character of Chronic Central Nervous System HIV Infection. <i>Seminars in Neurology</i> , 2014, 34, 007-013.	1.4	29
85	Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection. <i>Journal of Neuroinflammation</i> , 2014, 11, 199.	7.2	33
86	Peripheral Neuropathy in Primary HIV Infection Associates With Systemic and Central Nervous System Immune Activation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 303-310.	2.1	34
87	An Example of Genetically Distinct HIV Type 1 Variants in Cerebrospinal Fluid and Plasma During Suppressive Therapy. <i>Journal of Infectious Diseases</i> , 2014, 209, 1618-1622.	4.0	47
88	Longitudinal Characterization of Depression and Mood States Beginning in Primary HIV Infection. <i>AIDS and Behavior</i> , 2014, 18, 1124-1132.	2.7	28
89	Cerebral metabolite changes prior to and after antiretroviral therapy in primary HIV infection. <i>Neurology</i> , 2014, 83, 1592-1600.	1.1	70
90	Treatment of HIV in the CNS: Effects of Antiretroviral Therapy and the Promise of Non-Antiretroviral Therapeutics. <i>Current HIV/AIDS Reports</i> , 2014, 11, 353-362.	3.1	11

#	ARTICLE	IF	CITATIONS
91	Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy. <i>Journal of Neuroinflammation</i> , 2013, 10, 62.	7.2	55
92	HIV and Neurocognitive Dysfunction. <i>Current HIV/AIDS Reports</i> , 2013, 10, 235-243.	3.1	60
93	Approach to Cerebrospinal Fluid (CSF) Biomarker Discovery and Evaluation in HIV Infection. <i>Journal of NeuroImmune Pharmacology</i> , 2013, 8, 1147-1158.	4.1	37
94	Cerebrospinal Fluid and Neuroimaging Biomarker Abnormalities Suggest Early Neurological Injury in a Subset of Individuals During Primary HIV Infection. <i>Journal of Infectious Diseases</i> , 2013, 207, 1703-1712.	4.0	142
95	Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. <i>Aids</i> , 2012, 26, 1765-1774.	2.2	212
96	Central Nervous System Viral Invasion and Inflammation During Acute HIV Infection. <i>Journal of Infectious Diseases</i> , 2012, 206, 275-282.	4.0	434
97	HIV-1-Related Central Nervous System Disease: Current Issues in Pathogenesis, Diagnosis, and Treatment. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a007120-a007120.	6.2	180
98	Change in Brain Magnetic Resonance Spectroscopy after Treatment during Acute HIV Infection. <i>PLoS ONE</i> , 2012, 7, e49272.	2.5	99
99	HIV-1 Replication in the Central Nervous System Occurs in Two Distinct Cell Types. <i>PLoS Pathogens</i> , 2011, 7, e1002286.	4.7	203
100	Central Nervous System Immune Activation Characterizes Primary Human Immunodeficiency Virus 1 Infection Even in Participants With Minimal Cerebrospinal Fluid Viral Burden. <i>Journal of Infectious Diseases</i> , 2011, 204, 753-760.	4.0	125
101	Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. <i>AIDS Research and Therapy</i> , 2010, 7, 15.	1.7	186
102	Compartmentalization and Clonal Amplification of HIV-1 Variants in the Cerebrospinal Fluid during Primary Infection. <i>Journal of Virology</i> , 2010, 84, 2395-2407.	3.4	142
103	HIV-1 Viral Escape in Cerebrospinal Fluid of Subjects on Suppressive Antiretroviral Treatment. <i>Journal of Infectious Diseases</i> , 2010, 202, 1819-1825.	4.0	255
104	Compartmentalized Human Immunodeficiency Virus Type 1 Originates from Long-Lived Cells in Some Subjects with HIV-1-Associated Dementia. <i>PLoS Pathogens</i> , 2009, 5, e1000395.	4.7	132
105	Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection. <i>PLoS ONE</i> , 2009, 4, e6877.	2.5	77
106	Persistent Intrathecal Immune Activation in HIV-1-Infected Individuals on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 168-173.	2.1	96
107	Antiretroviral Treatment Effect on Immune Activation Reduces Cerebrospinal Fluid HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 544-552.	2.1	52
108	Enfuvirtide Cerebrospinal Fluid (CSF) Pharmacokinetics and Potential use in Defining CSF HIV-1 Origin. <i>Antiviral Therapy</i> , 2008, 13, 369-374.	1.0	27

#	ARTICLE	IF	CITATIONS
109	Immune Activation of the Central Nervous System Is Still Present after >4 Years of Effective Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2007, 196, 1779-1783.	4.0	164
110	Defining and Evaluating HIV-Related Neurodegenerative Disease and Its Treatment Targets: A Combinatorial Approach to Use of Cerebrospinal Fluid Molecular Biomarkers. <i>Journal of NeuroImmune Pharmacology</i> , 2007, 2, 112-119.	4.1	45
111	Treatment Benefit on Cerebrospinal Fluid HIV RNA Levels in the Setting of Systemic Virological Suppression and Failure. <i>Journal of Infectious Diseases</i> , 2006, 194, 1686-1696.	4.0	83
112	Missense Mutations in the Rod Domain of the Lamin A/C Gene as Causes of Dilated Cardiomyopathy and Conduction-System Disease. <i>New England Journal of Medicine</i> , 1999, 341, 1715-1724.	27.0	1,195
113	Immunological, Cognitive and Psychiatric Outcomes after Initiating EFV- and DTG-based Antiretroviral Therapy during Acute HIV Infection. <i>Clinical Infectious Diseases</i> , 0, , .	5.8	5